ASC42 clinical trials
Also written ASC42.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses ASC42 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASC42
- 3
Studies by the year they started
5 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Gannex Pharma Co., Ltd. (3) · Ascletis Pharmaceuticals Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ASC42 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy SubjectsCompletedPhase 1Gannex Pharma Co., Ltd.NCT04679129Written as ASC42
- Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisCompletedPhase 2Gannex Pharma Co., Ltd.NCT05190523Written as ASC42 5 mg
- Drug Interaction Study of ASC42 With AtorvastatinCompletedPhase 1Gannex Pharma Co., Ltd.NCT05464628Written as ASC42
- Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBVCompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT05107778Written as ASC42 10mg
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy SubjectsCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04965337Written as ASC42